Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Microbot Medical ( (MBOT) ) just unveiled an update.
On October 1, 2025, Microbot Medical announced that it has received its first patent in Japan for its core LIBERTY® System technology, which includes a compact robotic device for manipulating surgical tools. This patent is part of the company’s strategy to broaden its global intellectual property portfolio, following recent patents in the U.S., China, and Israel. The company, which recently received FDA clearance for the LIBERTY® System, is focusing on the U.S. market but is also exploring other global markets that accept FDA-cleared devices. This development is expected to protect and monetize its innovative technology, enhancing its market positioning and potential adoption in strategic markets like Japan.
The most recent analyst rating on (MBOT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. is a breakthrough medical device company focused on transforming endovascular procedures through advanced robotic technology. Its flagship product, the LIBERTY® Endovascular Robotic System, is the first single-use, remotely operated robotic solution designed for precision, efficiency, and provider safety. The company is backed by a strong intellectual property portfolio and is committed to innovation in endovascular care.
Average Trading Volume: 4,052,311
Technical Sentiment Signal: Buy
Current Market Cap: $145.7M
Learn more about MBOT stock on TipRanks’ Stock Analysis page.